The mammalian skull vault consists mainly of 5 flat bones, the paired frontals and parietals, and the unpaired interparietal. All of these bones are formed by intramembranous ossification within a layer of mesenchyme, the skeletogenic membrane, located between the dermal mesenchyme and the meninges surrounding the brain. While the frontal bones are of neural crest in origin, the parietal bones arise from mesoderm. The present study is a characterization of frontal and parietal bones at their molecular level, aiming to highlight distinct differences between the neural crest-derived frontal and mesodermal-derived parietal bone. We performed a detailed comparative gene expression profile of FGF ligands and their receptors known to play crucial role in skeletogenesis. This analysis revealed that a differential expression pattern of the major FGF osteogenic molecules and their receptors exists between the neural crest-derived frontal bone and the paraxial mesoderm-derived parietal bone. Particularly, the expression of ligands such as Fgf-2, Fgf-9 and Fgf-18 was upregulated in frontal bone on embryonic day 17.5, postnatal day 1 and postnatal day 60 mice. Frontal bone also elaborated higher levels of Fgf receptor 1, 2 and 3 transcripts versus parietal bone. Taken together, these data suggest that the frontal bone is a domain with higher FGF-signaling competence than parietal bone.

Keywords:
Neural crest, Mesoderm, Origin, Frontal, Parietal, Bone, FGF/FGFR, Mouse
1.
Chai, Y., X. Jiang, Y. Ito, P. Bringas Jr., J. Han, D.H. Rowitch, P. Soriano, A.P. McMahon, H.M. Sucov (2000) Fate of the mammalian cranial neural crest during tooth and mandibular morphogenesis. Development 127: 1671–1679.
2.
Coffin, J.D., R.Z. Florkiewicz, J. Neumann, T. Mort-Hopkins, G.W. Dorn 2nd, P. Lightfoot, R. German, P.N. Howles, A. Kier, B.A. O’Toole, et al. (1995) Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol Biol Cell 6: 1861–1873.
3.
Deng, C., A. Wynshaw-Boris, F. Zhou, A. Kuo, P. Leder (1996) Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84: 911–921.
4.
Ducy, P., R. Zhang, V. Geoffroy, A.L. Ridall, G. Karsenty (1997) Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89: 747–754.
5.
Eswarakumar, V.P., E. Monsonego-Ornan, M. Pines, I. Antonopoulou, G.M. Morriss-Kay, P. Lonai (2002) The IIIc alternative of Fgfr2 is a positive regulator of bone formation. Development 129: 3783–3793.
6.
Fakhry, A., C. Ratisoontorn, C. Vedhachalam, I. Salhab, E. Koyama, P. Leboy, M. Pacifici, R.E. Kirschner, H.D. Nah (2005) Effects of FGF-2/-9 in calvarial bone cell cultures: differentiation stage-dependent mitogenic effect, inverse regulation of BMP-2 and noggin, and enhancement of osteogenic potential. Bone 36: 254–266.
7.
Govindarajan, V., P.A. Overbeek (2006) FGF9 can induce endochondral ossification in cranial mesenchyme. BMC Dev Biol 6: 7.
8.
Hung, I.H., K. Yu, K.J. Lavine, D.M. Ornitz (2007) FGF9 regulates early hypertrophic chondrocyte differentiation and skeletal vascularization in the developing stylopod. Dev Biol 307: 300–313.
9.
Iseki, S., A.O. Wilkie, G.M. Morriss-Kay (1999) Fgfr1 and Fgfr2 have distinct differentiation- and proliferation-related roles in the developing mouse skull vault. Development 126: 5611–5620.
10.
Jiang, X., S. Iseki, R.E. Maxson, H.M. Sucov, G.M. Morriss-Kay (2002) Tissue origins and interactions in the mammalian skull vault. Dev Biol 241: 106–116.
11.
Karsenty G. (2001) Minireview: transcriptional control of osteoblast differentiation. Endocrinology 142: 2731–2733.
12.
Karsenty, G., E.F. Wagner (2002) Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2: 389–406.
13.
Kim, H.J., J.H. Kim, S.C. Bae, J.Y. Choi, H.J. Kim, H.M. Ryoo (2003) The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem 278: 319–326.
14.
Liu, Z., J. Xu, J.S. Colvin, D.M. Ornitz (2002) Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev 16: 859–869.
15.
Mansukhani, A., P. Bellosta, M. Sahni, C. Basilico (2000) Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol 149: 1297–1308.
16.
Marie, P.J. (2003) Fibroblast growth factor signaling controlling osteoblast differentiation. Gene 316: 23–32.
17.
Morriss-Kay, G.M. (2001) Derivation of the mammalian skull vault. J Anat 199: 143–151.
18.
Muenke, M., U. Schell (1995) Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet 11: 308–313.
19.
Naski, M.C., D.M. Ornitz (1998) FGF signaling in skeletal development. Front Biosci 3: d781–d794.
20.
Ohbayashi, N., M. Shibayama, Y. Kurotaki, M. Imanishi, T. Fujimori, N. Itoh, S. Takada (2002) FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev 16: 870–879.
21.
Ornitz, D.M., N. Itoh (2001) Fibroblast growth factors. Genome Biol 2: REVIEWS3005.
22.
Quarto, N., K.D. Fong, M.T. Longaker (2005) Gene profiling of cells expressing different FGF-2 forms. Gene 356: 49–68.
23.
Quarto N., M.T. Longaker (2006) FGF-2 inhibits osteogenesis in mouse adipose tissue-derived stromal cells and sustains their proliferative and osteogenic potential state. Tissue Eng 12: 1405–1418.
24.
Rice, D.P., R. Rice, I. Thesleff (2003) Fgfr mRNA isoforms in craniofacial bone development. Bone 33: 14–27.
25.
Wilkie A.O., G.M. Morriss-Kay, E.Y. Jones, J.K. Heath (1995a) Functions of fibroblast growth factors and their receptors. Curr Biol 5: 500–507.
26.
Wilkie A.O., S.F. Slaney, M. Oldridge, M.D. Poole, G.J. Ashworth, A.D. Hockley, R.D. Hayward, D.J. David, L.J. Pulleyn, P. Rutland, et al., (1995b) Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 9: 165–172.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.